Other diseases
Osteogenesis imperfecta
成骨不全症
A group of inherited disorders marked by bones that fracture easily.
Definition adapted from MeSH (US National Library of Medicine)
- hospitals in mainland China
- 59
- cities
- 31
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 14% of the world's English-language research papers on osteogenesis imperfecta, 2021–2025 (11% in 2016–2020), and 2% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
59 hospitals in 31 cities
Order: papers led on osteogenesis imperfecta, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 1 papers or 1 trial on osteogenesis imperfecta, or was a site in 1 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens osteogenesis imperfecta in that city. 21 more cities are in the menu below.
- 14 papers ledNo open trial led
- 7 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 5 papers ledNo open trial led
- 4 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 14
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 17 papers led1 hospital
- 8 papers led2 hospitals
- 7 papers led3 hospitals
- 7 papers led2 hospitals
- 5 papers led1 hospital
- 4 papers led2 hospitals
- 2 papers led2 hospitals
- 2 papers led2 hospitals
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 1 paper led1 hospital
- 1 paper led1 hospital
- 0 papers led0 hospitals
open trial on osteogenesis imperfecta in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 13 Nov 2026, with at least one listed hospital as lead sponsor or site, and at least one listed hospital's site marked open. 0 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingA Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07557446
Age 12 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Shanghai, Shenzhen, Suzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Additional research sources
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
Where these numbers come from
Papers
99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 13 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.